Login to Your Account

MacroGenics, Lilly Ink $1B Deal For Diabetes Drug Teplizumab

By Donna Young

Friday, October 19, 2007
MacroGenics Inc. has entered into a deal with Eli Lilly and Co. that could be worth more than $1 billion to develop and commercialize the biotech's lead product teplizumab. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription